Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
September 25th, 2019
6.8K views
Presented here is a protocol for the effective suppression of hepatitis B virus (HBV) replication in mice by utilizing adoptive cell transfer (ACT) of stem cell-derived viral antigen (Ag)-specific T lymphocytes. This procedure may be adapted for potential ACT-based immunotherapy of HBV infection.
Overview
This article presents a protocol for the suppression of hepatitis B virus (HBV) replication in mice using adoptive cell transfer (ACT) of stem cell-derived viral antigen-specific T lymphocytes. The method emphasizes the use of iPSC-derived T cells with a naive phenotype and a single type T cell receptor.
Key Study Components
Area of Science
- Immunology
- Virology
- Cellular Therapy
Background
- Hepatitis B virus (HBV) is a significant global health issue.
- Adoptive cell transfer (ACT) is a promising therapeutic approach.
- iPSC-derived T cells offer advantages in specificity and phenotype.
- Understanding T cell differentiation is crucial for effective therapy.
Purpose of Study
- To develop a protocol for HBV suppression in a mouse model.
- To utilize iPSC-derived T cells for targeted therapy.
- To assess the effectiveness of ACT in viral replication control.
Methods Used
- Transduction of iPSCs with HBV-specific T cell receptor genes.
- Co-culture of transduced iPSCs on OP9-DL1/DL4 monolayers.
- Monitoring cell morphology during differentiation.
- Harvesting and centrifugation of differentiated T cells.
Main Results
- Successful differentiation of HBV-specific CD8-positive T cells.
- Demonstrated potential for ACT in suppressing HBV replication.
- Characterization of T cell responses in the mouse model.
- Insights into the efficacy of iPSC-derived T cells in therapy.
Conclusions
- The protocol provides a foundation for ACT-based immunotherapy.
- iPSC-derived T cells show promise in targeting HBV.
- Further studies are needed to optimize therapeutic applications.
Frequently Asked Questions
What is the significance of using iPSC-derived T cells?
iPSC-derived T cells have a naive phenotype and a single type T cell receptor, enhancing their specificity and effectiveness in targeting HBV.
How does the protocol contribute to HBV research?
The protocol outlines a method for effectively suppressing HBV replication, providing a potential avenue for immunotherapy.
What are the main advantages of this technique?
The main advantages include the specificity of T cells and their naive phenotype, which may improve therapeutic outcomes.
What are the next steps after this study?
Future research will focus on optimizing the protocol and assessing its efficacy in clinical settings.
Can this method be adapted for other viral infections?
Yes, the principles of ACT and iPSC-derived T cells may be applicable to other viral infections.
What is the role of OP9-DL1/DL4 monolayers in the protocol?
OP9-DL1/DL4 monolayers provide a supportive environment for the differentiation of iPSC-derived T cells.
Executive Industry Relevance
This protocol enables the generation of stem cell-derived, antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy, addressing a critical gap in targeting persistent viral reservoirs like HBV. By providing a scalable source of virus-specific T cells with defined receptor specificity and naive phenotype, the method supports preclinical evaluation of T-cell-based therapeutics. It offers a mechanistic platform to assess functional antiviral activity in vivo, informing go/no-go decisions in early immunotherapy development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of T-cell receptor specificity and functional avidity against defined viral antigens in a controlled system.
- Operational Value: Provides a renewable source of antigen-specific T cells with uniform phenotype for reproducible preclinical testing.
- Predictive Value: Supports assessment of T-cell-mediated viral suppression as a biomarker for therapeutic potency prior to lead candidate selection.
Screening & Assay Development
- Assay Readiness: Generates validated effector T cells capable of antigen-dependent cytokine production and cytotoxic activity for functional assay validation.
- Quantitative Output: Enables measurement of interferon-gamma secretion and viral antigen expression as pharmacodynamic readouts.
- Reproducibility: Standardized differentiation and stimulation protocols support consistent T-cell production across experiments.
Translational & Preclinical Research
- Disease Relevance: Utilizes a murine HBV model with hydrodynamic plasmid delivery to mimic viral antigen expression and replication dynamics.
- Translational Continuity: Demonstrates adoptive transfer of iPSC-derived T cells resulting in reduced viral DNA and surface antigen in liver and blood.
- Risk De-risking: Provides mechanistic evidence of antigen-specific T-cell function in suppressing viral replication, supporting IND-enabling studies.
Pipeline & Workflow Integration
The method fits within the immunotherapy discovery continuum, linking target validation through T-cell generation to preclinical efficacy testing in viral challenge models.
- Discovery Biology: Supports hypothesis testing of TCR specificity and T-cell function in antiviral immunity using defined antigen stimulation.
- Screening: Enables production of standardized T-cell batches for screening immunomodulatory agents or checkpoint modulators that enhance T-cell activity.
- Analytics: Generates quantifiable readouts including intracellular cytokine flow cytometry, ELISA for IFN-gamma, and qPCR for viral DNA suppression.
- Translational Research: Connects in vitro T-cell differentiation to in vivo antiviral effects in liver tissue, supporting biomarker alignment.
- Enterprise Reuse: The iPSC-T cell differentiation platform can be adapted to other viral antigens by changing TCR transduction, enabling pipeline-wide application.
Operational & Enterprise Impact
- Scientific Value: Mechanistic de-risking of T-cell efficacy through direct demonstration of HBV replication suppression in vivo.
- Operational Value: Defined differentiation protocol yields clonal, naive T cells reducing variability in preclinical assays.
- Strategic Value: Informs early go/no-go decisions by providing functional evidence of antigen-specific T-cell antiviral activity.
- Portfolio Impact: Enables risk-adjusted prioritization of immunotherapy candidates based on measurable target engagement and viral suppression.
Implementation Considerations
- Requires expertise in iPSC culture, TCR transduction, and hematopoietic differentiation on stromal monolayers.
- Dependent on access to OP9-DL1/DL4 feeder cells, cytokine supplements (Flt3L), and peptide-pulsed antigen-presenting cells for T-cell stimulation.
- Necessitates standardized assays for T-cell phenotyping (CD3/CD8), intracellular cytokine staining, and viral load quantification.
- Adaptation to other antigens requires re-cloning of antigen-specific TCRs and validation of HLA restriction in the model system.
- Practical limitations include the time-intensive differentiation process (~28 days) and need for murine models to assess in vivo functionality.
Biopharma FAQs
Why is single T cell receptor specificity important for target validation?
Using T cells with a single defined TCR allows precise measurement of antigen-specific function without confounding signals from polyclonal populations, supporting accurate assessment of target engagement and therapeutic specificity in preclinical models.
How does isolating the independent variable (antigen-specific T cells) fit the discovery pipeline?
By generating uniform iPSC-derived T cells with defined specificity, the method isolates the therapeutic variable, enabling clear attribution of observed antiviral effects to the T-cell product rather than mixed immune responses.
What quantitative dependent variable measurements enable assessment of T-cell efficacy?
The protocol measures HBV DNA levels via real-time PCR and HBV surface antigen expression via immunofluorescence and immunohistochemistry, providing quantitative readouts of viral suppression in liver and blood following T-cell transfer.
Why do replication requirements matter for cross-functional collaboration?
Standardized differentiation, stimulation, and adoptive transfer protocols ensure reproducible T-cell production and function across laboratories, enabling consistent data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementation?
Implementation requires the ability to perform group comparisons using statistical tests (e.g., t-tests or ANOVA) on viral load and antigen expression data to determine significant differences between T-cell-treated and control mice.
Chapters in this video
0:04
Title
0:34
Antigen (Ag)‐ Specific CD8+ T cell Generation
2:01
Hydrodynamic Herpes B Virus (HBV) Plasmid Delivery for HBV Replication Induction
2:43
HBV Replication Reduction
3:38
HBV Replication Reduction Analysis
5:30
Results: Representative Effects of Stem Cell-Derived Viral Ag-Specific T Lymphocyte HBV Replication Suppression
6:58
Conclusion
